| A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations (NCT07345689) | Xuanzhu Biopharmaceutical Co., Ltd. | 2026-01-30 |
| Drug-drug Interaction Study of Rifampin and Anaprazole Sodium (NCT07330531) | Xuanzhu Biopharmaceutical Co., Ltd. | 2026-01-04 |
| A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. (NCT07010107) | Xuanzhu Biopharmaceutical Co., Ltd. | 2025-07-30 |
| A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human (NCT05836805) | Xuanzhu Biopharmaceutical Co., Ltd. | 2023-05-01 |
| A Study of KM602 in Patients With Advanced Solid Tumors (NCT05766527) | Xuanzhu Biopharmaceutical Co., Ltd. | 2023-04-01 |
| A Study of KM501 in Patients With Solid Tumors (NCT05804864) | Xuanzhu Biopharmaceutical Co., Ltd. | 2023-04-01 |
| A Study of XZB-0004 in Patients With Solid Tumors (NCT05772455) | Xuanzhu Biopharmaceutical Co., Ltd. | 2023-03-24 |
| To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS (NCT05740917) | Xuanzhu Biopharmaceutical Co., Ltd. | 2023-02-01 |
| A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis (NCT05604261) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-12-01 |
| Drug-drug Interaction Study of XZP-3621 Tablet (NCT05586568) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-11-15 |
| A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC (NCT05482087) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-09-01 |
| A Clinical Trial of XZP-3287 for Material Balance (NCT05478109) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-08-02 |
| A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. (NCT05320874) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-04-01 |
| A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer (NCT05257395) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-03-14 |
| A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib (NCT05204628) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-02-07 |
| Food Effect and Mass Balance Study of XZP-3621 Tablets (NCT05034120) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-12-23 |
| A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors (NCT04996121) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-12-06 |
| A Clinical Trial of XZP-6019 Tablets in Healthy Subjects (NCT05063968) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-11-30 |
| A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer (NCT05077449) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-11-16 |
| Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects (NCT04951765) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-08-01 |
| Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects (NCT04951713) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-07-01 |
| A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer (NCT05055232) | Xuanzhu Biopharmaceutical Co., Ltd. | 2019-03-12 |